The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma

PURPOSE: High-dose aldesleukin (HD IL-2) received FDA approval for the treatment of mRCC in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducte...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: McDermott, David F., Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A., Clark, Joseph I., Sosman, Jeffrey A., Dutcher, Janice P., Logan, Theodore F., Curti, Brendan D., Ernstoff, Marc S., Appleman, Leonard, Wong, Michael K.K., Khushalani, Nikhil I., Oleksowicz, Leslie, Vaishampayan, Ulka N., Mier, James W., Panka, David J., Bhatt, Rupal S., Bailey, Alexandra S., Leibovich, Bradley C., Kwon, Eugene D., Kabbinavar, Fairooz F., Belldegrun, Arie S., Figlin, Robert A., Pantuck, Allan J., Regan, Meredith M., Atkins, Michael B.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315731/
https://ncbi.nlm.nih.gov/pubmed/25424850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1520
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki